An interventional study of Multi-element, team-oriented treatment in Schizophrenia, Schizoaffective Disorder and Schizophreniform Disorder, sponsored by Research Foundation for Mental Hygiene, Inc.. Completed at 2 sites in United States. Open to participants aged 15 Years to 35 Years. Per ClinicalTrials.gov, last updated 2016-11-03.
Sponsored by Research Foundation for Mental Hygiene, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,466 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.
Among the 1,466 studies in Schizophrenia with a site in United States, this one is the 664th largest by enrollment of the 1,320 interventional ones that give a count, is one of 74 that started in 2010, is one of 480 with no phase, and was the 575th registered.
3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.
Browse Schizophrenia studies →148 of the 1,466 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 18–55
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 15 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,466 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 228 · Phase 2 271 · Phase 3 218 · Phase 4 193
First in 1983; this study’s year is marked. 74 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is close to the median of 70 across 2,953 interventional studies indexed under Schizophrenia.
Median enrollment 66 across the 1,320 interventional studies, 163 across the 128 observational. Of the 1,234 that completed or were terminated, 603 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
517 of 1,466 have an industry lead sponsor. The 10 most frequent:
Research Foundation for Mental Hygiene, Inc. is the lead sponsor of 35 studies on the registry; none are open to participants now.
Research Foundation for Mental Hygiene, Inc. has 4 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
52 of the studies in Schizophrenia with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT03817502Phase 3Gedeon Richter Plc.Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | 2026-12-15 |
| NCT06191965Phase 3Mclean HospitalMitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction | 2027-01-31 |
| NCT07184619Phase 3Newron Pharmaceuticals SPAEvenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia | 2027-03-31 |
| NCT07363577Phase 3LB Pharmaceuticals Inc.Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia | 2027-06 |
Add all 52 to your calendar (.ics) → With an account.
Among the 1,466 studies in Schizophrenia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the effectiveness of an experimental treatment intervention for adolescents and adults who have experienced their first episode of psychosis during the past two years.
The DUP sub-study will collect pathways to care information that will be used to inform the development and pilot testing of strategies that aim to reduce DUP among individuals experiencing a first episode of psychosis.
This study is part of the National Institute of Mental Health's Recovery After an Initial Schizophrenia Episode (RAISE) Project. The RAISE Project seeks to fundamentally change the trajectory and prognosis of schizophrenia through coordinated and aggressive treatment in the earliest stages of illness. This study, the RAISE Connection Program, is one of the two independent research studies that NIMH has funded to conduct the NIMH RAISE Project. The Connection Program is being supported in whole or in part with Federal funds from the American Recovery and Reinvestment Act of 2009 and the NIMH, National Institutes of Health, Department of Health and Human Services. The Connection Program aims to to assess the effectiveness of a Team-based intervention for individuals with a first psychotic episode, observing outcomes over time for our study participants. When tracking outcomes, the Connection Program will make comparisons with what is known about the natural history of untreated first episode of psychosis as well as usual care outcomes from other experimental studies.
This study is for people who have experienced symptoms such as hallucinations, unusual thoughts or beliefs, or disorganized thinking for the first time during the past two years. Without treatment, many people have a difficult time with these symptoms, which can be very upsetting and also make it hard to socialize, study, or work.
People have different wishes and needs, and it is not clear what combination of treatments and services is best for any one person. There are many possible treatments and services, such as medications, talk therapy, case management, and school and job counseling. This study will adapt and evaluate the impact of a comprehensive and integrated treatment intervention for first episode psychosis to be delivered in real-world practice settings to promote symptomatic recovery, minimize disability, and maximize social, academic, and vocational functioning.
Participation in this study will last up to 2 years. At the baseline visit, participants will be enrolled to receive the experimental intervention. During the study period, participants will take part in research interviews every three to six months for a total of 6 interviews. Each of these research interviews will take 1.5 to 3 hours to complete. Assessments of participants' health condition, overall function and illness severity, employment status, academic performance, and social functioning will be conducted during these research interviews. In addition to assessing functioning and illness severity, this study will also address substance abuse and utilization of healthcare services. Participants will also be measured for their height, weight and waist circumference. This portion of the study concluded in December 2013.
The RAISE-DUP contract modification seeks additional information on the referral pathways that resulted in enrollment in the RAISE Connection Program from individuals who participated in RAISE Connection Program services and their family members. Information gathered through qualitative research interviews will be used to inform the development and pilot testing of outreach, education, and engagement intervention strategies, to serve the larger goal of reducing the duration of untreated psychosis among individuals experiencing a first episode of psychosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: Multi-element, team-oriented treatment
Participants will receive treatment and services based on their needs coordinated by a small team that is led by a clinical coordinator. Services that are available to the participants include social skills training, medication treatment to address symptoms, education and employment advising, and substance use treatment.
The Mental Illness Research Education and Clinical Center Global Assessment of Functioning (MIRECC GAF)
This measures occupational functioning, social functioning and symptom severity.
Time frame: Measured at baseline
The Mental Illness Research Education and Clinical Center Global Assessment of Functioning (MIRECC GAF)
Time frame: Measured at Month 6
The Mental Illness Research Education and Clinical Center Global Assessment of Functioning (MIRECC GAF)
Time frame: Measured at Month 12
The Mental Illness Research Education and Clinical Center Global Assessment of Functioning (MIRECC GAF)
Time frame: Measured at Month 18
The Mental Illness Research Education and Clinical Center Global Assessment of Functioning (MIRECC GAF)
Time frame: Measured at Month 24
Pathways to Care Qualitative Interview
This assessment gathers information on help-seeking events and participant recommendations.
Time frame: Measured at baseline
The Clinical Global Impression (CGI) - Severity scale
This assesses the level of severity of illness.
Time frame: Measured at baseline
Calgary Depression Scale
This assesses depression in people with schizophrenia.
Time frame: Measured at baseline
Positive and Negative Syndrome Scale for Schizophrenia (PANSS)
This measures the presence and severity of symptoms of schizophrenia.
Time frame: Measured at baseline
The Clinical Global Impression (CGI) - Severity scale
This assesses the level of severity of illness.
Time frame: Measured at Month 6
The Clinical Global Impression (CGI) - Severity scale
This assesses the level of severity of illness.
Time frame: Measured at Month 12
The Clinical Global Impression (CGI) - Severity scale
This assesses the level of severity of illness.
Time frame: Measured at Month 18
The Clinical Global Impression (CGI) - Severity scale
This assesses the level of severity of illness.
Time frame: Measured at Month 24
Calgary Depression Scale
This assesses depression in people with schizophrenia.
Time frame: Measured at Month 6
Calgary Depression Scale
This assesses depression in people with schizophrenia.
Time frame: Measured at Month 12
Calgary Depression Scale
This assesses depression in people with schizophrenia.
Time frame: Measured at Month 18
Calgary Depression Scale
This assesses depression in people with schizophrenia.
Time frame: Measured at Month 24
Positive and Negative Syndrome Scale for Schizophrenia (PANSS)
This measures the presence and severity of symptoms of schizophrenia.
Time frame: Measured at Month 6
Positive and Negative Syndrome Scale for Schizophrenia (PANSS)
This measures the presence and severity of symptoms of schizophrenia.
Time frame: Measured at Month 12
Positive and Negative Syndrome Scale for Schizophrenia (PANSS)
This measures the presence and severity of symptoms of schizophrenia.
Time frame: Measured at Month 18
Positive and Negative Syndrome Scale for Schizophrenia (PANSS)
This measures the presence and severity of symptoms of schizophrenia.
Time frame: Measured at Month 24
The record gives a start of Oct 2010, a primary completion of Jan 2015 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Research Foundation for Mental Hygiene, Inc.